BUZZ-AAR shares rise as first-quarter results beat expectations
路透社2026/09/29 10:56September 29 - ** Shares of aviation aftermarket services provider AAR (AIR.N) rose about 7% in premarket trading, reaching $123
** On Monday, AAR reported adjusted earnings per share of $1.49 for the first quarter, compared to $1.08 in the same period last year
** Full-year sales growth rate is expected to be at the low end of the double-digit percentage range, versus a previous forecast of the low end of the double-digit to teen percentage range
** The company also said (link) it will acquire a 65% controlling stake in aircraft maintenance company MRO Holdings for about $1.8 billion
** The transaction is expected to close in AAR’s fiscal third quarter ending February 2027
** According to documents filed with the U.S. Securities and Exchange Commission (SEC), the company will pay a termination fee of $100 million or $150 million if the transaction is terminated due to failure to obtain antitrust approval
** Based on data compiled by London Stock Exchange Group (LSEG), the median target price from eight brokers covering the stock is $145
** As of the close of the previous trading day, the stock is up about 40% year to date
(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for the convenience of readers. Reuters accepts no liability for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Iovance Biotherapeutics Raises 2026 Revenue Guidance
AstraZeneca (AZN.US) invests in Summit (SMMT.US), gaining positive outlooks from JPMorgan and Citi: Cancer drug strategy awaits validation
Analysts from JPMorgan and Citi have welcomed the deal between AstraZeneca and Summit Therapeutics, stating that it aligns with AstraZeneca's cancer strategy.